Jacobsen N
Haematologisk afd, Rigshospitalet, København.
Nord Med. 1995;110(12):314-5.
Severe acquired aplastic anaemia is associated with high morbidity and mortality despite improvement in the results obtained both with bone marrow transplantation and with immunosuppressive treatment. Early bone marrow transplantation is the treatment of choice for patients under 45 years of age, if the neutrophil granulocyte count is less than 0.2-0.5 x 10(9)/l and an HLA-identical sibling donor is available. Other patients should receive primary immunosuppression with antithymocyte globulin, cyclosporin and glucocorticoid in combination with granulocyte colony-stimulating factor. If they fail to respond after three months, and a donor is available, such patients may be treated with bone marrow transplantation. However, transplantation with marrow from donors other than HLA-identical siblings is still at an experimental stage.
尽管骨髓移植和免疫抑制治疗的效果有所改善,但严重获得性再生障碍性贫血仍与高发病率和死亡率相关。对于45岁以下、中性粒细胞计数低于0.2 - 0.5×10⁹/L且有 HLA 相同的同胞供者的患者,早期骨髓移植是首选治疗方法。其他患者应接受抗胸腺细胞球蛋白、环孢素和糖皮质激素联合粒细胞集落刺激因子的初始免疫抑制治疗。如果三个月后无反应且有供者,此类患者可接受骨髓移植治疗。然而,使用 HLA 相同同胞以外供者的骨髓进行移植仍处于实验阶段。